Compare Expedia Group Inc (EXPE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Incyte Corporation — how do they compare? Expedia Group Inc trades at $268.54 (market cap $32.06B), while Incyte Corporation trades at $116.15 (market cap $22.99B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays a 0.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EXPE | INCY | |
|---|---|---|
Market Cap | $32.06B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $118.52 |
52-Week Low | $178.06 | $67.38 |
Enterprise Value | $30.97B | $19.01B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $264.76, down 0.57% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with revenue growth to $14.73B in 2025 and consistent earnings beats, including Q1 2026 EPS of $1.96 versus $1.41 expected. Recent developments include a strategic partnership with Allegiant Travel and positive analyst coverage highlighting growth potential. Valuation metrics include a P/E of 23.6 and P/S of 2.29, indicating reasonable pricing relative to peers.
The outlook for EXPE is positive, driven by robust travel demand, strategic initiatives, and a consensus price target of $292.09 implying ~10% upside. Key risks include macroeconomic sensitivity affecting travel spending and competitive pressures. Institutional sentiment is bullish with 45% buy ratings, though investors should monitor execution on growth targets and industry cyclicality.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
